Vertex Pharmaceuticals Incorporated Common Stock (VRTX)
NASDAQ
Real-time Data
01:30 PM
Day's Range
498.9052 wk Range
402.58Overview - VRTX - Vertex Pharmaceuticals Incorporated Common Stock
Key Statistics
Valuation
Enterprise Value
122.05B
P/E (Trailing)
‪29.62‬
P/E (Forward)
‪25.11‬
PEG Ratio
‪3.72‬
Price / Sales (TTM)
‪10.16‬
Price / Book
‪6.31‬
EV / EBITDA
‪23.93‬
Profitability
Gross Margin
‪85.32%‬
Profit Margin
‪34.99%‬
Operating Margin
‪38.05%‬
Return on Assets
‪11.92%‬
Return on Equity
‪23.54%‬
Ownership
Shares Outstanding
253.34M
Float
252.68M
Short % of Shares Outstanding
‪2.10%‬
Held by Insiders
‪0.21%‬
Held by Institutions
‪97.94%‬
Price stats
Beta
‪0.32‬
50-Day Avg
‪517.57‬
200-Day Avg
‪473.37‬
Dividends
Payout Ratio
‪0.00%‬
Analyst Consensus
32 analysts
Average price target
‪$ 563.12‬Shariah Compliance
Report Date: Feb 19, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - VRTX - Vertex Pharmaceuticals Incorporated Common Stock
Peers - VRTX - Vertex Pharmaceuticals Incorporated Common Stock
Peer Comparison
Compared with companies in Biotechnology listed on NASDAQ.
- VRTXNASDAQVertex Pharmaceuticals Incorporated Common Stock127.92BMarket Cap+20.18%52-week change29.62P/E (Trailing)‪34.99%‬Profit Margin
- ARGXNASDAQArgenx SE57.50BMarket Cap+14.28%52-week change34.96P/E (Trailing)‪32.26%‬Profit Margin
- ALNYNASDAQAlnylam Pharmaceuticals, Inc.29.40BMarket Cap-105.72%52-week change38.35P/E (Trailing)‪16.12%‬Profit Margin
- BNTXNASDAQBioNTech SE American Depositary Share24.34BMarket Cap-8.52%52-week change160.80P/E (Trailing)‪-63.63%‬Profit Margin
- ASNDNASDAQAscendis Pharma A/S14.99BMarket Cap+7.48%52-week change17.72P/E (Trailing)‪70.84%‬Profit Margin
- BBIONASDAQBridgeBio Pharma Inc.13.14BMarket Cap+18.80%52-week change-17.80P/E (Trailing)‪-97.02%‬Profit Margin
- BMRNNASDAQBioMarin Pharmaceutical Inc.11.06BMarket Cap+2.75%52-week change154.54P/E (Trailing)‪2.14%‬Profit Margin
Profile Summary - VRTX - Vertex Pharmaceuticals Incorporated Common Stock
About
Vertex Pharmaceuticals Incorporated Common Stock represents ownership in Vertex Pharmaceuticals Incorporated, a global biotechnology company focused on discovering, developing, manufacturing, and commercializing medicines for serious diseases. The company’s current portfolio is centered on cystic fibrosis therapies…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
